Joshua Jennings
Stock Analyst at TD Cowen
(3.17)
# 1,089
Out of 5,241 analysts
86
Total ratings
43.21%
Success rate
3.25%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $1 → $1.5 | $0.8253 | +81.75% | 5 | May 14, 2026 | |
| TMDX TransMedics Group | Maintains: Buy | $190 → $120 | $66.13 | +81.46% | 10 | May 6, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Hold | $189 → $163 | $146.95 | +10.92% | 2 | May 4, 2026 | |
| DXCM DexCom | Maintains: Buy | $84 → $75 | $66.95 | +12.02% | 3 | May 1, 2026 | |
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $4.10 | +46.34% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $25.91 | +31.22% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $56.81 | +76.03% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $230.00 | +8.70% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $82.16 | +18.06% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.00 | +275.00% | 1 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $20 | $16.96 | +17.92% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $5.54 | +170.76% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.70 | +94.81% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $154.61 | +109.56% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $86.08 | +38.24% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $34.49 | +73.96% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $77.53 | +3.19% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $3.86 | +1,065.80% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $18.33 | +118.22% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $317.75 | +25.89% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $65.55 | -8.47% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $13.86 | +145.31% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.73 | +167.46% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $16.69 | +49.84% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $88.82 | +46.36% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.73 | +189.02% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $78.58 | +48.89% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $8.22 | +45.99% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $9.99 | +175.28% | 3 | Sep 5, 2018 |
Humacyte
May 14, 2026
Maintains: Buy
Price Target: $1 → $1.5
Current: $0.8253
Upside: +81.75%
TransMedics Group
May 6, 2026
Maintains: Buy
Price Target: $190 → $120
Current: $66.13
Upside: +81.46%
Becton, Dickinson and Company
May 4, 2026
Maintains: Hold
Price Target: $189 → $163
Current: $146.95
Upside: +10.92%
DexCom
May 1, 2026
Maintains: Buy
Price Target: $84 → $75
Current: $66.95
Upside: +12.02%
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $4.10
Upside: +46.34%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $25.91
Upside: +31.22%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $56.81
Upside: +76.03%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $230.00
Upside: +8.70%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $82.16
Upside: +18.06%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.00
Upside: +275.00%
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $16.96
Upside: +17.92%
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $5.54
Upside: +170.76%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $7.70
Upside: +94.81%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $154.61
Upside: +109.56%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $86.08
Upside: +38.24%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $34.49
Upside: +73.96%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $77.53
Upside: +3.19%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $3.86
Upside: +1,065.80%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $18.33
Upside: +118.22%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $317.75
Upside: +25.89%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $65.55
Upside: -8.47%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $13.86
Upside: +145.31%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.73
Upside: +167.46%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $16.69
Upside: +49.84%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $88.82
Upside: +46.36%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.73
Upside: +189.02%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $78.58
Upside: +48.89%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $8.22
Upside: +45.99%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $9.99
Upside: +175.28%